Special Issue

Novel Targeted Radiopharmaceuticals for Diagnosis and Therapy

Message from the Guest Editors

The development of new radiopharmaceuticals designed for the diagnosis and therapy of various diseases is a rapidly growing field of research towards precision health solutions. As a result, the remarkable clinical potential of radiolabeled probes is currently receiving increased attention from clinicians and pharmaceutical companies. However, a challenging aspect in the acceptance of the novel probes remains the multidisciplinary nature of the research that requires expertise in (radio)chemistry, radiobiology, medicine, and medical physics, which consequently necessitates collaborative approaches. This Special Issue of *Molecules* is open for articles (reviews, research papers and communications) with a focus on strategies for the synthesis and radiolabeling of novel targeted radiopharmaceuticals as well as in vitro and in vivo evaluations of their diagnostic and therapeutic performances. Subjects might include but are not limited to designs of new chelators for various radiometals, targeting vectors and linkers for their conjugation, or the introduction of radiohalogens into the structure of biomolecules.

Guest Editors

Dr. Kristina Djanashvili
Department of Biotechnology, Delft University of Technology, Delft, The Netherlands

Dr. Sara Lacerda
Center of Molecular Biophysics, CNRS, Orléans, France

Deadline for manuscript submissions

closed (31 July 2024)

Molecules

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed

mdpi.com/si/113917

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

mdpi.com/journal/molecules

Molecules

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed

mdpi.com/journal/molecules

MDPI

About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt
Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).